Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis

Publisher： Karger

E-ISSN： 1661-3805|11|6|406-410

ISSN： 1661-3791

Source： Breast Care, Vol.11, Iss.6, 2016-12, pp. : 406-410

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

By  

Breast Care, Vol. 2, Iss. 4, 2007-08 ,pp. : 227-233

Karger

Access to resources Recommend Favorite

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 168-171

Karger

Access to resources Recommend Favorite

Node-Negative Breast Cancer: Which Patients Should Be Treated?

By  

Breast Care, Vol. 3, Iss. 4, 2008-08 ,pp. : 237-243

Karger

Access to resources Recommend Favorite

The Role of Blue Dye in Sentinel Node Detection for Breast Cancer: A Retrospective Study of 203 Patients

By  

Breast Care, Vol. 11, Iss. 2, 2016-04 ,pp. : 128-132

Karger

Access to resources Recommend Favorite